Items where Subject is "gastrointestinal stromal tumors"

Group by: Authors | Item Type
Jump to: A | B | C | D | G | H | I | M | N | P | R | S
Number of items at this level: 40.

A

Aberle, M. R., Burkhart, R. A., Tiriac, H., Olde Damink, S. W. M., Dejong, C. H. C., Tuveson, D. A., van Dam, R. M. (January 2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg, 105 (2). e48-e60. ISSN 0007-1323

Agaram, N. P., Besmer, P., Wong, G. C., Guo, T., Socci, N. D., Maki, R. G., DeSantis, D., Brennan, M. F., Singer, S., DeMatteo, R. P., Antonescu, C. R. (January 2007) Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Clin Cancer Res, 13 (1). pp. 170-81. ISSN 1078-0432 (Print)1078-0432 (Linking)

Agaram, N. P., Laquaglia, M. P., Ustun, B., Guo, T., Wong, G. C., Socci, N. D., Maki, R. G., DeMatteo, R. P., Besmer, P., Antonescu, C. R. (May 2008) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res, 14 (10). pp. 3204-15. ISSN 1078-0432 (Print)1078-0432 (Linking)

Agaram, N. P., Wong, G. C., Guo, T., Maki, R. G., Singer, S., Dematteo, R. P., Besmer, P., Antonescu, C. R. (October 2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer, 47 (10). pp. 853-9. ISSN 1098-2264 (Electronic)1045-2257 (Linking)

Antonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., Leversha, M. A., Jeffrey, P. D., Desantis, D., Singer, S., Brennan, M. F., Maki, R. G., DeMatteo, R. P. (June 2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 11 (11). pp. 4182-90. ISSN 1078-0432 (Print)1078-0432 (Linking)

Antonescu, C. R., Sommer, G., Sarran, L., Tschernyavsky, S. J., Riedel, E., Woodruff, J. M., Robson, M., Maki, R., Brennan, M. F., Ladanyi, M., DeMatteo, R. P., Besmer, P. (August 2003) Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res, 9 (9). pp. 3329-37. ISSN 1078-0432 (Print)1078-0432 (Linking)

Antonescu, C. R., Viale, A., Sarran, L., Tschernyavsky, S. J., Gonen, M., Segal, N. H., Maki, R. G., Socci, N. D., DeMatteo, R. P., Besmer, P. (May 2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res, 10 (10). pp. 3282-90. ISSN 1078-0432 (Print)1078-0432 (Linking)

B

Berman, E., Girotra, M., Cheng, C., Chanel, S., Maki, R., Shelat, M., Strauss, H. W., Fleisher, M., Heller, G., Farooki, A. (July 2013) Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res, 37 (7). pp. 790-4. ISSN 1873-5835 (Electronic)0145-2126 (Linking)

Berman, E., Nicolaides, M., Maki, R. G., Fleisher, M., Chanel, S., Scheu, K., Wilson, B. A., Heller, G., Sauter, N. P. (May 2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med, 354 (19). pp. 2006-13. ISSN 1533-4406 (Electronic)0028-4793 (Linking)

Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H., Baker, L. H., Maki, R. G., Tanaka, M., Hecht, J. R., Heinrich, M. C., Fletcher, C. D., Crowley, J. J., Borden, E. C. (February 2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 26 (4). pp. 626-32. ISSN 1527-7755 (Electronic)0732-183X (Linking)

C

Chen, J., Guo, T., Zhang, L., Qin, L. X., Singer, S., Maki, R. G., Taguchi, T., Dematteo, R., Besmer, P., Antonescu, C. R. (February 2012) CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes Cancer, 51 (2). pp. 186-95. ISSN 1098-2264 (Electronic)1045-2257 (Linking)

Chi, P., Chen, Y., Zhang, L., Guo, X., Wongvipat, J., Shamu, T., Fletcher, J. A., Dewell, S., Maki, R. G., Zheng, D., Antonescu, C. R., Allis, C. D., Sawyers, C. L. (October 2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 467 (7317). pp. 849-53. ISSN 1476-4687 (Electronic)0028-0836 (Linking)

Corless, C. L., Ballman, K. V., Antonescu, C. R., Kolesnikova, V., Maki, R. G., Pisters, P. W., Blackstein, M. E., Blanke, C. D., Demetri, G. D., Heinrich, M. C., von Mehren, M., Patel, S., McCarter, M. D., Owzar, K., DeMatteo, R. P. (May 2014) Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol, 32 (15). pp. 1563-70. ISSN 1527-7755 (Electronic)0732-183X (Linking)

D

DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Corless, C., Kolesnikova, V., von Mehren, M., McCarter, M. D., Norton, J., Maki, R. G., Pisters, P. W., Demetri, G. D., Brennan, M. F., Owzar, K., American College of Surgeons Oncology Group Intergroup Adjuvant, Gist Study Team for the Alliance for Clinical Trials in Oncolog (September 2013) Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg, 258 (3). pp. 422-9. ISSN 1528-1140 (Electronic)0003-4932 (Linking)

DeMatteo, R. P., Maki, R. G., Singer, S., Gonen, M., Brennan, M. F., Antonescu, C. R. (March 2007) Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg, 245 (3). pp. 347-52. ISSN 0003-4932 (Print)0003-4932 (Linking)

Dematteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., Patel, S., McCarter, M. D., Polikoff, J. A., Tan, B. R., Owzar, K., American College of Surgeons Oncology Group Intergroup Adjuvant, Gist Study Team (March 2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 373 (9669). pp. 1097-104. ISSN 1474-547X (Electronic)0140-6736 (Linking)

Dematteo, R. P., Gold, J. S., Saran, L., Gonen, M., Liau, K. H., Maki, R. G., Singer, S., Besmer, P., Brennan, M. F., Antonescu, C. R. (February 2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 112 (3). pp. 608-15. ISSN 0008-543X (Print)0008-543X (Linking)

Demetri, G. D., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D., Van den Abbeele, A. D., Corless, C. L., Antonescu, C. R., George, S., Morgan, J. A., Chen, M. H., Bello, C. L., Huang, X., Cohen, D. P., Baum, C. M., Maki, R. G. (September 2009) Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res, 15 (18). pp. 5902-9. ISSN 1078-0432 (Print)1078-0432 (Linking)

Demetri, G. D., Reichardt, P., Kang, Y. K., Blay, J. Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., Badalamenti, G., Blackstein, M., Le Cesne, A., Schoffski, P., Maki, R. G., Bauer, S., Nguyen, B. B., Xu, J., Nishida, T., Chung, J., Kappeler, C., Kuss, I., Laurent, D., Casali, P. G., investigators, Grid study (January 2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381 (9863). pp. 295-302. ISSN 1474-547X (Electronic)0140-6736 (Linking)

Dickson, M. A., Okuno, S. H., Keohan, M. L., Maki, R. G., D'Adamo, D. R., Akhurst, T. J., Antonescu, C. R., Schwartz, G. K. (January 2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol, 24 (1). pp. 252-7. ISSN 1569-8041 (Electronic)0923-7534 (Linking)

Dumont, A. G., Rink, L., Godwin, A. K., Miettinen, M., Joensuu, H., Strosberg, J. R., Gronchi, A., Corless, C. L., Goldstein, D., Rubin, B. P., Maki, R. G., Lazar, A. J., Lev, D., Trent, J. C., von Mehren, M. (May 2012) A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol, 23 (5). pp. 1335-40. ISSN 1569-8041 (Electronic)0923-7534 (Linking)

G

Gold, J. S., Gonen, M., Gutierrez, A., Broto, J. M., Garcia-del-Muro, X., Smyrk, T. C., Maki, R. G., Singer, S., Brennan, M. F., Antonescu, C. R., Donohue, J. H., DeMatteo, R. P. (November 2009) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol, 10 (11). pp. 1045-52. ISSN 1474-5488 (Electronic)1470-2045 (Linking)

Gold, J. S., van der Zwan, S. M., Gonen, M., Maki, R. G., Singer, S., Brennan, M. F., Antonescu, C. R., De Matteo, R. P. (January 2007) Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol, 14 (1). pp. 134-42. ISSN 1068-9265 (Print)1068-9265 (Linking)

Gordon, J. K., Magid, S. K., Maki, R. G., Fleisher, M., Berman, E. (June 2010) Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Leuk Res, 34 (6). pp. 827-9. ISSN 1873-5835 (Electronic)0145-2126 (Linking)

Guo, T., Agaram, N. P., Wong, G. C., Hom, G., D'Adamo, D., Maki, R. G., Schwartz, G. K., Veach, D., Clarkson, B. D., Singer, S., DeMatteo, R. P., Besmer, P., Antonescu, C. R. (August 2007) Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res, 13 (16). pp. 4874-81. ISSN 1078-0432 (Print)1078-0432 (Linking)

Guo, T., Hajdu, M., Agaram, N. P., Shinoda, H., Veach, D., Clarkson, B. D., Maki, R. G., Singer, S., Dematteo, R. P., Besmer, P., Antonescu, C. R. (November 2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res, 15 (22). pp. 6862-70. ISSN 1078-0432 (Print)1078-0432 (Linking)

H

Heinrich, M., Rankin, C., Blanke, C. D., Demetri, G. D., Borden, E. C., Ryan, C. W., von Mehren, M., Blackstein, M. E., Priebat, D. A., Tap, W. D., Maki, R. G., Corless, C. L., Fletcher, J. A., Owzar, K., Crowley, J. J., Benjamin, R. S., Baker, L. H. (July 2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol, 3 (7). pp. 944-952. ISSN 2374-2437

Heinrich, M. C., Maki, R. G., Corless, C. L., Antonescu, C. R., Harlow, A., Griffith, D., Town, A., McKinley, A., Ou, W. B., Fletcher, J. A., Fletcher, C. D., Huang, X., Cohen, D. P., Baum, C. M., Demetri, G. D. (November 2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 26 (33). pp. 5352-9. ISSN 1527-7755 (Electronic)0732-183X (Linking)

I

Italiano, A., Cioffi, A., Coco, P., Maki, R. G., Schoffski, P., Rutkowski, P., Le Cesne, A., Duffaud, F., Adenis, A., Isambert, N., Bompas, E., Blay, J. Y., Casali, P., Keohan, M. L., Toulmonde, M., Antonescu, C. R., Debiec-Rychter, M., Coindre, J. M., Bui, B. (May 2012) Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol, 19 (5). pp. 1551-9. ISSN 1534-4681 (Electronic)1068-9265 (Linking)

Italiano, A., Saada, E., Cioffi, A., Poulette, S., Bouchet, S., Molimard, M., Adenis, A., Isambert, N., Collard, O., Le Cesne, A., Maki, R. G., Bui, B. (December 2013) Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. Target Oncol, 8 (4). pp. 295-300. ISSN 1776-260X (Electronic)1776-2596 (Linking)

M

Maki, R. G. (October 2012) The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). Clin Sarcoma Res, 2 (1). p. 21. ISSN 2045-3329 (Electronic)2045-3329 (Linking)

McCarter, M. D., Antonescu, C. R., Ballman, K. V., Maki, R. G., Pisters, P. W., Demetri, G. D., Blanke, C. D., von Mehren, M., Brennan, M. F., McCall, L., Ota, D. M., DeMatteo, R. P., American College of Surgeons Oncology Group Intergroup Adjuvant , Team (July 2012) Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg, 215 (1). 53-9; discussion 59. ISSN 1879-1190 (Electronic)1072-7515 (Linking)

N

Norden-Zfoni, A., Desai, J., Manola, J., Beaudry, P., Force, J., Maki, R., Folkman, J., Bello, C., Baum, C., DePrimo, S. E., Shalinsky, D. R., Demetri, G. D., Heymach, J. V. (May 2007) Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res, 13 (9). pp. 2643-50. ISSN 1078-0432 (Print)1078-0432 (Linking)

P

Prakash, S., Sarran, L., Socci, N., DeMatteo, R. P., Eisenstat, J., Greco, A. M., Maki, R. G., Wexler, L. H., LaQuaglia, M. P., Besmer, P., Antonescu, C. R. (April 2005) Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol, 27 (4). pp. 179-87. ISSN 1077-4114 (Print)1077-4114 (Linking)

R

Raut, C. P., Espat, N. J., Maki, R. G., Araujo, D. M., Trent, J., Williams, T. F., Purkayastha, D. D., DeMatteo, R. P. (November 2018) Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol, 4 (12). e184060. ISSN 2374-2437

Robson, M. E., Glogowski, E., Sommer, G., Antonescu, C. R., Nafa, K., Maki, R. G., Ellis, N., Besmer, P., Brennan, M., Offit, K. (February 2004) Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res, 10 (4). pp. 1250-4. ISSN 1078-0432 (Print)1078-0432 (Linking)

Roubaud, G., Kind, M., Coindre, J. M., Maki, R. G., Bui, B., Italiano, A. (March 2012) Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. Ann Oncol, 23 (3). pp. 804-5. ISSN 1569-8041 (Electronic)0923-7534 (Linking)

Rubin, B. P., Blanke, C. D., Demetri, G. D., Dematteo, R. P., Fletcher, C. D., Goldblum, J. R., Lasota, J., Lazar, A., Maki, R. G., Miettinen, M., Noffsinger, A., Washington, M. K., Krausz, T., Cancer Committee, College of American Pathologists (February 2010) Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med, 134 (2). pp. 165-70. ISSN 1543-2165 (Electronic)0003-9985 (Linking)

Ryan, D. P., Puchalski, T., Supko, J. G., Harmon, D., Maki, R., Garcia-Carbonero, R., Kuhlman, C., Winkelman, J., Merriam, P., Quigley, T., Jimeno, J., Manola, J., Demetri, G. D. (2002) A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist, 7 (6). pp. 531-8. ISSN 1083-7159 (Print)1083-7159 (Linking)

S

Seandel, M., Shia, J., Linkov, I., Maki, R. G., Antonescu, C. R., Dupont, J. (October 2006) The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clin Cancer Res, 12 (20 Pt ). pp. 6203-4. ISSN 1078-0432 (Print)1078-0432 (Linking)

This list was generated on Thu Mar 28 20:57:18 2024 EDT.
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving